Tumor SOCS3 protein expression, instead of SOCS3 promoter methylation status, predicts chemotherapy response and prognosis in advanced NSCLC patients

Jinhong Wang; Dong Kang; Yu Yao; Anna Shen; Deguang Yang; Tao Zhou

doi:10.18632/oncotarget.23108

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 12/11/2017.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Research Papers:

Tumor SOCS3 protein expression, instead of SOCS3 promoter methylation status, predicts chemotherapy response and prognosis in advanced NSCLC patients

Jinhong Wang, Dong Kang, Yu Yao, Anna Shen, Deguang Yang and Tao Zhou _

Jinhong Wang1, Dong Kang2, Yu Yao3, Anna Shen4 , Deguang Yang4 and Tao Zhou4

1 Department of respiration, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China

2 Hui qiao Department, South Hospital of Southern Medical University, Guangzhou, Guangdong, China

3 Department of Anesthesiology, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China

4 Department of Cardiovascular, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China

Correspondence to:

Tao Zhou, email: [email protected]

Keywords: suppressor of cytokine signaling 3; non-small cell lung cancer; promoter methylation; treatment response; prognosis

Received: April 07, 2017 Accepted: July 26, 2017 Epub: December 11, 2017

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23108

Publication Alerts

Withdrawal Notice

Research Papers:

Tumor SOCS3 protein expression, instead of SOCS3 promoter methylation status, predicts chemotherapy response and prognosis in advanced NSCLC patients